Webinars

We are delighted to welcome you to this webinar, sponsored by Exact Sciences*, about the changing role of pathologists in the area of precision oncology.

The goal of this webinar is to share the learnings around the ease of onboarding a liquid biopsy solution in a laboratory setting

In this webinar, Dr. Jantus-Lewintre shares her lab's experience evaluating the Oncomine Comprehensive Assay Plus

In this Bionano in Motion webinar, we explore the utility and validity of an innovative strategy, proposed by Dr. Kolhe’s lab, from Augusta University, that combines optical genome mapping (OGM) with a comprehensive 523-gene next-generation sequencing (NGS) panel. This unique approach was meticulously evaluated against more traditional methods including karyotyping, fluorescent in situ hybridization (FISH), and a 54-gene NGS panel.

We are thrilled to invite you to our upcoming online webinar, where we will delve into groundbreaking research on the spatial organization of immune cells in human tumors and its impact on immunotherapy outcomes.

In this webinar, Dr Federico Cappuzzo will speak about clinical implications of liquid biopsy-based CGP for lung cancer patients, discussing current clinical evidence and sharing his vision on future applications.

Join Illumina and Parse Biosciences for a webinar where our invited speaker will present results of his recent single-cell study.

Immune therapy has emerged as the new frontier of cancer treatment.

Roche Tissue Diagnostics invites you to learn more about the importance of identifying each level of HER2 expression.

Pathologists from the US, Japan and Europe participate in a LIVE panel, to share their expert voices.

This webinar will discuss these approaches to spatial analysis and include an example of both protein and mRNA assessment of tissue using DSP as a biomarker discovery tool.

Join Illumina for an educational webinar on the new EU IVD Regulation.

In this webinar, Dr. Amelie Bonafond will present the current sequencing (via whole-exome sequencing) of all the patients with common T2D visiting the department of Diabetology of Liège Hospital (n > 4000 participants).

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized.

Patients diagnosed with CML 20 years ago could live for around five years.